BREYANZI® MAKES COMPLETE AND
LASTING REMISSION POSSIBLE
Home > How Breyanzi Can Help > Results With Breyanzi > LBCL
RECLAIM TOMORROW: ACHIEVE PROLONGED RESULTS WITH A ONE-TIME INFUSION*
In 3 clinical studies, over 300 people were treated with Breyanzi for their large B-cell lymphoma (LBCL). Patients included those who had received a stem cell transplant as well as those who did not. Explore the clinical trial results below. View the potential side effects >
MORE LIFE, FEWER CANCER EVENTS
Who was in Study 1 and what were the results?
A clinical study evaluated 184 adult patients with LBCL who had received 1 line of treatment that either did not work or stopped working within 12 months after the first treatment given. The goal of the study was to determine the safety and efficacy of Breyanzi compared to chemotherapy followed by high-dose therapy and a stem cell transplant (standard therapy).
This is also called event-free survival (EFS). An event is the cancer getting worse, failing to respond to cancer therapy, or needing to start a new lymphoma treatment.
At the first follow-up, the time without an event was 10.1 months with Breyanzi vs 2.3 months (median) with standard therapy.†
At 33.9 months follow-up (median)
This is called complete response, which was seen in 68 out of 92 people who received Breyanzi, compared to 40 out of 92 people who were treated with standard therapy.†
Complete response means there were no signs of cancer in the body, but it does not mean the cancer has been cured. The rest of the people who responded (12 out of 92 people) experienced a decrease of cancer in the body. This is called a partial response.
At 33.9 months follow-up (median)
This refers to the reduced risk of cancer coming back or getting worse, which was measured at about 3 years after receiving Breyanzi.
Who was in Study 2 and what were the results?
A clinical study evaluated 61 adult patients with LBCL who were not able to receive a stem cell transplant and who had received 1 line of treatment that either did not work or stopped working.
REMISSION IS POSSIBLE IN PEOPLE WHO CANNOT UNDERGO A STEM CELL TRANSPLANT
This is called overall response, which was seen in 49 out of 61 people. It measures a decrease or disappearance of cancer in the body.
This is called complete response, which was seen in 33 out of 61 people. Complete response means there were no signs of cancer in the body, but it does not mean the cancer has been cured.
The rest of the people who responded (16 out of 61 people) experienced a decrease of cancer in the body. This is called partial response.
RAPID REMISSION WAS SEEN, WITH MANY PEOPLE EXPERIENCING COMPLETE REMISSION WITHIN 1 MONTH
In the clinical study, complete response, or remission, was seen around 1 month (median) after infusion. This ranges from 0.8 months to 6.9 months.
LBCL, large B-cell lymphoma; R/R, relapsed or refractory.
*The treatment process includes blood collection, CAR T cell creation, administration, and side-effect monitoring. No maintenance therapy for the lymphoma is needed after Breyanzi as long as you are responding to treatment.
†Standard therapy was chemoimmunotherapy followed by high-dose therapy and a stem cell transplant in people who responded.
These are the results experienced by people in the Breyanzi clinical studies. Your results may be different.
RECLAIM TOMORROW: ACHIEVE PROLONGED RESULTS WITH A ONE-TIME INFUSION*
In 3 clinical studies, over 300 people were treated with Breyanzi for their large B-cell lymphoma (LBCL). Patients included those who had received a stem cell transplant as well as those who did not. Explore the clinical trial results below. View the potential side effects >
COMPLETE REMISSION IS POSSIBLE AFTER 2 OR MORE PRIOR TREATMENTS
Who was in Study 3 and what were the results?
A clinical study evaluated 192 adult patients with LBCL who had received at least 2 other types of treatment (including a prior stem cell transplant) that did not work or stopped working.
This is called overall response, which was seen in 141 out of 192 people. It measures a decrease or disappearance of cancer in the body.
Half of the patients with an overall response were still responding at 16.7 months.
This is called complete response, which was seen in 104 out of 192 people. Complete response means there were no signs of cancer in the body, but it does not mean the cancer has been cured. At the time of initial follow-up, for patients who had a complete response, at least half of the patients were still in remission.
The rest of the people who responded (37 out of 192 people) experienced a decrease of cancer in the body. This is called partial response.
LBCL, large B-cell lymphoma; R/R, relapsed or refractory.
*The treatment process includes blood collection, CAR T cell creation, administration, and side-effect monitoring. No maintenance therapy for the lymphoma is needed after Breyanzi as long as you are responding to treatment.
These are the results experienced by people in the Breyanzi clinical studies. Your results may be different.
Learn more about Breyanzi for the treatment of R/R LBCL
Get to know this CAR T cell therapy in detail, including the clinical trial results, safety information, and treatment process.
R/R, relapsed or refractory.